Advertisement

PharmacoEconomics

, Volume 5, Supplement 3, pp 27–34 | Cite as

Omeprazole vs Ranitidine in Reflux Oesophagitis in Sweden

  • Greger Lindberg
Article

Summary

This study compared the cost-effectiveness of 2 strategies for the treatment of reflux oesophagitis. In the first strategy, treatment began with ranitidine 300mg daily for 8 weeks. The alternative strategy began with omeprazole 20mg daily for 4 weeks, and continued with another 4 weeks of omeprazole 20mg daily if patients were unhealed after the first 4 weeks. Those who remained unhealed in both groups after 8 weeks of treatment were administered omeprazole 40mg once daily for 4 weeks. The average cost of treatment and follow-up endoscopies per healed week was Swedish krona (SEK)l 140 ($US1 = SEK8) in the ranitidine group, whereas with omeprazole treatment the average cost per healed week was SEK622. The omeprazole strategy was more effective (6.75 healed weeks in a 12-week period) than ranitidine (3.71 healed weeks) and, despite a higher daily cost of treatment, omeprazole resulted in a lower average cost per patient. Sensitivity analysis showed that the conclusion regarding omeprazole being more cost-effective than ranitidine was insensitive to all reasonable changes in the cost parameters. Healing rates from 3 clinical trials also support the robustness of the conclusion in terms of the effect parameter.

Keywords

Omeprazole Ranitidine Healing Rate Reflux Oesophagitis Ranitidine 150mg 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bate CM, Crowe JP, Dickinson RJ, Green JRB, Smith PM, et al. Reflux esophagitis resolves more rapidly with omeprazole 20mg once daily than with ranitidine 150mg twice daily: omeprazole 40mg once daily provides further benefit in unresponsive patients. British Journal of Clinical Research 2: 133–148, 1991Google Scholar
  2. Bate CM, Keeling PWN, O’Morain C, Wilkinson SP, Foster DN, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31: 969–972, 1990Google Scholar
  3. Blum AL, Wienbeck M, Schiessel R, Carlsson R. Omeprazole is superior to ranitidine in the treatment of reflux esophagitis. Hepato-Gastroenterology 36: 279, 1989Google Scholar
  4. Brunner G, Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scandinavian Journal of Gastroenterology 166 (Suppl.): 101–105, 1989CrossRefGoogle Scholar
  5. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903–912, 1988PubMedGoogle Scholar
  6. Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1: 349–351, 1987PubMedCrossRefGoogle Scholar
  7. Koelz HR. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scandinavian Journal of Gastroenterology 156 (Suppl.): 25–36, 1989Google Scholar
  8. Lindberg G, Lindström E, Marke LA, Nyren O, Seensalu R. Gastroskopi vid utredning av ont i magen. Stockholm: The Swedish Council on Technology Assessment in Health Care: 15–124, 1990Google Scholar
  9. Lindberg G, Lundquist P, Seensalu R, Linden B, Nilsson LH. Prospective evaluation of ‘GLADYS’ — a system for computer assisted diagnosis of dyspepsia. Theoretical Surgery 7: 169–176, 1992Google Scholar
  10. Lundell L, Backman L, Ekström P, Enander LH, Fausa O, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’ of H2-receptor antagonists. Alimentary Pharmacology and Therapeutics 4: 145–155, 1990PubMedCrossRefGoogle Scholar
  11. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scandinavian Journal of Gastroenterology 23: 625–632, 1988PubMedCrossRefGoogle Scholar
  12. Schaub N, Thomas JM, Misiewicz JJ, Lovell D, Trotman IF. Investigation of ranitidine 150mg bd or 300 mg bd in the treatment of reflux disease. Hepato-Gastroenterology 33: 208–213, 1986PubMedGoogle Scholar
  13. Sintonen H, Alander V. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. Journal of Health Economics 9: 85–101, 1990PubMedCrossRefGoogle Scholar
  14. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40mg) is superior to ranitidine in short-term treatment of ulcerative reflux oesophagitis. Digestive Diseases and Sciences 33: 523–529, 1988PubMedCrossRefGoogle Scholar
  15. Wesdorp IC, Dekker W, Klinkenberg-Knol EC. Treatment of reflux oesophagitis with ranitidine. Gut 24: 921–924, 1983PubMedCrossRefGoogle Scholar
  16. Zeitoun P, Rampal P, Barbier P, Isal JP, Eriksson S, et al. Omeprazole (20 mg/day) compared with ranitidine (150mg twice daily) in the treatment of reflux oesophagitis. Results of a randomised double-blind multicentre Franco-Belgian trial. Gastroenterologie Clinique et Biologique 13: 457–462, 1989PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 1994

Authors and Affiliations

  • Greger Lindberg
    • 1
  1. 1.Karolinska Institute, Department of Medicine, Division of GastroenterologyHuddinge University HospitalHuddingeSweden

Personalised recommendations